Rapid preparation of short-lived alpha particle emitting radioimmunopharmaceuticals

Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine
D MaDavid A Scheinberg

Abstract

Alpha emitting radionuclides are of considerable interest for targeted radioimmunotherapy. Generator supplied 213Bi emitting 8.5 MeV alpha particles with a 45.6 min half-life has been conjugated to a monoclonal antibody (HuM195-CHX-A-DTPA) for targeted therapy of leukemia in a clinical trial. The clinical dose preparation of pharmaceutical formulation by a pair of skilled radiochemists took 25 min, which corresponds, to an overall decay loss of 30% of the initial 213Bi activity eluted from the generator. In order to allow more widespread and practical clinical use of targeted 213Bi alpha particle therapy, we developed a new procedure that is simpler, more rapid and adaptable to a hospital pharmacy. The new 10 min process includes a tandem elution and labeling, and an anion exchange column purification method that can be reproducibly used.

References

Apr 1, 1995·Nuclear Medicine and Biology·T K NikulaDavid A Scheinberg
Jun 1, 1995·Nuclear Medicine Communications·F M KaspersenR Molinet
Feb 1, 1993·Nuclear Medicine Communications·M W GeerlingsR van der Hout
Jan 1, 1996·Acta Oncologica·M R Zalutsky, D D Bigner
Sep 2, 1998·European Journal of Nuclear Medicine·Michael R McDevittDavid A Scheinberg
Apr 24, 1999·Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine·Michael R McDevittDavid A Scheinberg

Citations

Apr 21, 2005·European Journal of Nuclear Medicine and Molecular Imaging·Olivier CouturierM Chérel
Dec 7, 2011·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Young-Seung Kim, Martin W Brechbiel
Nov 10, 2007·Dalton Transactions : an International Journal of Inorganic Chemistry·Martin W Brechbiel
Aug 4, 2012·Future Medicinal Chemistry·Jorge A R SalvadorSamuel M Silvestre
Dec 1, 2010·Journal of Applied Toxicology : JAT·Anna Giulia CattaneoGiovanni Bernardini
May 30, 2014·Targeted Oncology·Evan D ReadTerrence J Piva
Nov 22, 2005·Radiation Research·Rong Wang, Jeffrey A Coderre

Related Concepts

Alpha Radiation
Monoclonal Antibodies
Bismuth
Ion-Exchange Chromatography Procedure
Clinical Trials
Half-Life
Radioisotopes
Acute Myeloid Leukemia, M1
Radioimmunoconjugates
Radiopharmaceuticals

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Related Papers

Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine
D MaDavid A Scheinberg
Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine
Michael R McDevittDavid A Scheinberg
European Journal of Nuclear Medicine
Michael R McDevittDavid A Scheinberg
Proceedings of the National Academy of Sciences of the United States of America
Meili ZhangThomas A Waldmann
© 2021 Meta ULC. All rights reserved